<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04637620</url>
  </required_header>
  <id_info>
    <org_study_id>CMUH103-REC2-130</org_study_id>
    <nct_id>NCT04637620</nct_id>
  </id_info>
  <brief_title>NMDA Modulation in Major Depressive Disorder</brief_title>
  <official_title>NMDA Modulation in Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Science and Technology, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China Medical University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Most of the current antidepressants for major depressive disorder (MDD) are based upon the&#xD;
      monoamine hypothesis which cannot fully explain the etiology of depression. NMDA hypofunction&#xD;
      has been implicated in the pathophysiology of depression. Therefore, this study will examine&#xD;
      the efficacy and safety as well as cognitive function improvement of an NMDA enhancer (NMDAE)&#xD;
      in the treatment of MDD in the adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Major depressive disorder (MDD) is a complex and multi-factorial disorder. Most of the&#xD;
      current antidepressants are based upon the monoamine hypothesis which cannot fully explain&#xD;
      the etiology of depression. Many patients have significant side effects after treatment with&#xD;
      antidepressants which hamper the motivation for treatment and medication adherence. NMDA&#xD;
      hypofunction has been implicated in the pathophysiology of depression. MDD is often&#xD;
      associated with cognitive deficits which are not necessarily recovered by current&#xD;
      antidepressants. The NMDA receptor regulates synaptic plasticity, memory, and cognition. In&#xD;
      our previous studies, cognitive improvement has been observed with treatment of NMDA&#xD;
      enhancers. Therefore, this study will examine the efficacy and safety as well as cognitive&#xD;
      function improvement of NMDAE in the treatment of MDD in the general adults by comparing with&#xD;
      sertraline (a selective serotonin reuptake inhibitor [SSRI]) and placebo. The investigators&#xD;
      will enroll non-elderly adult patients with MDD for an 8-week treatment. All patients will be&#xD;
      randomly assigned into three groups: NMDAE, sertraline, or placebo. The investigators will&#xD;
      biweekly measure clinical performances and side effects. Cognitive functions will be assessed&#xD;
      at baseline and at endpoint of treatment by a battery of tests. The efficacy of three groups&#xD;
      will be compared.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hamilton Rating Scale for Depression</measure>
    <time_frame>week 0, 2, 4, 6, 8</time_frame>
    <description>Assessment of depressive symptoms Minimum value: 0, maximum value:52, the higher scores mean a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Global Assessment of Functioning</measure>
    <time_frame>Week 0, 2, 4, 6, 8</time_frame>
    <description>Assessment of global improvement. Minimum value: 1, maximum value:100, the higher scores mean a better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Perceived Stress Scale</measure>
    <time_frame>week 0, 2, 4, 6, 8</time_frame>
    <description>Assessment of stress and anxiety symptoms Minimum value: 0, maximum value:56, the higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale (VAS)</measure>
    <time_frame>week 0, 2, 4, 6, 8</time_frame>
    <description>Assessment of pain Minimum value: 0, maximum value:10, the higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression</measure>
    <time_frame>week 0, 2, 4, 6, 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (SF-36)</measure>
    <time_frame>week 0, 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Continuous Performance Test</measure>
    <time_frame>week 0, 8</time_frame>
    <description>Assessment of sustained attention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wisconsin Card Sorting Test</measure>
    <time_frame>week 0, 8</time_frame>
    <description>Assessment of abstract and shift set</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Logical Memory Test of the Wechsler Memory Scale</measure>
    <time_frame>week 0, 8</time_frame>
    <description>Assessment of episodic memory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digit Span</measure>
    <time_frame>week 0, 8</time_frame>
    <description>Assessment of verbal working memory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spatial Span</measure>
    <time_frame>week 0, 8</time_frame>
    <description>Assessment of nonverbal working memory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Category Fluency</measure>
    <time_frame>week 0, 8</time_frame>
    <description>Assessment of speed of processing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trail Marking A</measure>
    <time_frame>week 0, 8</time_frame>
    <description>Assessment of speed of processing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WAIS-III Digit Symbol-Coding</measure>
    <time_frame>week 0, 8</time_frame>
    <description>Assessment of speed of processing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) V2.0</measure>
    <time_frame>week 0, 8</time_frame>
    <description>Assessment of social cognition</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>NMDAE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An NMDA enhancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SSRI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sertraline (selective serotonin reuptake inhibitor)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NMDAE</intervention_name>
    <description>Use of an NMDA enhancer for the treatment of MDD</description>
    <arm_group_label>NMDAE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>Use of SSRI as an active comparator</description>
    <arm_group_label>SSRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Cap</intervention_name>
    <description>Use of placebo as a comparator</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a DSM-5 (American Psychiatric Association) diagnosis of MDD&#xD;
&#xD;
          -  17-item Hamilton Rating Scale for Depression total score â‰¥ 18&#xD;
&#xD;
          -  Free of antidepressant drugs for at least 2 weeks&#xD;
&#xD;
          -  Agree to participate in the study and provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current substance abuse or history of substance dependence in the past 6 months&#xD;
&#xD;
          -  History of epilepsy, head trauma, stroke or other serious medical or neurological&#xD;
             illness which may interfere with the study&#xD;
&#xD;
          -  Bipolar depression, schizophrenia or other psychotic disorder&#xD;
&#xD;
          -  Moderate-severe suicidal risks&#xD;
&#xD;
          -  Severe cognitive impairment&#xD;
&#xD;
          -  Initiating or stopping formal psychotherapy within six weeks prior to enrollment&#xD;
&#xD;
          -  A history of severe adverse reaction to SSRIs&#xD;
&#xD;
          -  A treatment-resistant history (that is, they have failed to respond to two or more&#xD;
             different classes of antidepressants with adequate dosage and treatment duration&#xD;
&#xD;
          -  A history of previously received electroconvulsive therapy&#xD;
&#xD;
          -  Inability to follow protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hsien-Yuan Lane, M.D., Ph.D</last_name>
    <phone>886 4 22052121</phone>
    <phone_ext>1855</phone_ext>
    <email>hylane@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Psychiatry, China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hsien-Yuan Lane, M.D., Ph.D</last_name>
      <phone>886 4 22052121</phone>
      <phone_ext>1855</phone_ext>
      <email>hylane@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 11, 2020</study_first_submitted>
  <study_first_submitted_qc>November 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Major depressive disorder</keyword>
  <keyword>NMDA</keyword>
  <keyword>Selective serotonin reuptake inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

